Incysus, Ltd logo

Incysus, Ltd

Incysus, (University of Alabama at Birmingham spinoff) is a biopharma company focused on the development of an innovative gamma-delta (??) T cell immunotherapy for the treatment of cancers.

Incysus inlicensed novel cellular therapy called Drug-Resistant Immunotherapy technology from The University of Alabama at Birmingham (UAB), Emory University and Childrens Healthcare of Atlanta. Incysus immuno-oncology programs include activated and gene modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.incysus.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
79 Madison Avenue, 2nd Floor,NY 10016
New York
United States
Email
Contact Number
+1 646-820-8474

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Incysus through its technology is genetically modified gamma-delta (??) T cells, to addresses the key challenges that other T cell immunotherapies face when targeting cold, low mutation cancers. T cell therapies utlizes the ?? T cells, are antigen-specific and may not eliminate the entire tumor. Incysus relies on ?? T cells because they do not require antigen processing to detect target cells, and they penetrate and kill solid tumors more effectively than ?? cells.